Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion StudyPRNewsWire • 06/30/21
Compugen Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 AxisPRNewsWire • 06/29/21
Compugen's COM701 Shows Treatment Durability Beyond One Year in Solid Tumor PatientsBenzinga • 06/08/21
Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual MeetingPRNewsWire • 06/08/21
Compugen Management to Discuss COM701 Data Presented at ASCO at Event Hosted by Truist SecuritiesPRNewsWire • 06/01/21
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/13/21
Compugen to Participate at SITC's Targets for Cancer Immunotherapy: A Deep Dive Seminar SeriesPRNewsWire • 05/11/21
Compugen Announces Expansion of Research Collaboration with Johns Hopkins University for a Novel Myeloid Target Discovered by CompugenPRNewsWire • 05/10/21
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual MeetingPRNewsWire • 04/29/21
Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, ImmunotherapyPRNewsWire • 04/27/21
Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer ImmunotherapyPRNewsWire • 03/09/21
Compugen: Serious Partnerships, Tremendous Potential, But Several Years To WaitSeeking Alpha • 02/28/21
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
Compugen's COM701 Shows Ongoing Durable Signals In Early-Stage Solid Tumor StudiesBenzinga • 02/25/21
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody ProductsPRNewsWire • 12/23/20
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/07/20
Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory BoardPRNewsWire • 09/30/20
Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT AntibodyPRNewsWire • 09/08/20